Stephen Nimer, MD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses how next-generation sequencing (NGS) is being used to understand the epigenetic landscape in low-risk MDS. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
